PHARMACEUTICA COMPOSITION FOR THE TREATMENT OF ACUTE MYOCARDIAL ISCHEMIA

Abstract: Defibrotide, a polydeoxyribonucleotide, obtained by extraction from animal organs. is the active ingredient of compositions for the treatment of acute states of myocardial ischemia and infarction.

Description: The present invention relates to the use of Defibrotide as the active ingredient for the preparation of a pharmaceutical composition for the prevention and the treatment of acute pathological states of the myocardium, such as acute ischemia, with or without necrosis of the myocardium (acute infarction). The pathogenetic mechanisms of the acute myocardial infarction are not yet fully undestood. In recent years the role of the coronary spasm in the phathogenesis of some forms of angina has been revalued and the hypothesis has been raised that the acute myocardial infarction might in some cases be caused by an extended coronary spasm possibly followed, downstream of the functional stenosis, by alterations of the blood flow and of the vascular wall, with stasis and subsequent platelet aggregation, release of thromboxane (TXA₂) and then thrombosis. The TXA₂ may potentiate the vasospastic phaenomenon which can be extended to other areas, thus involving potential vessels forming part of the side circulation. To date, for the treatment of the myocardial ischemia and infarction, some therapeutical proposals have been brought forward and/or practiced, based on the use of: coronary vasodilators, nitrates beta-blocking compounds calcium-antagonizing substances prostacyclin The nitroderivatives are vasodilating compounds directly acting on all the vessels; the vasodilation as induced by these drugs on the side circulation might cause the intramyocardial blood flow to be redistributed in the presence of a coronary occlusion. In some experimental researches nitroglycerin has been able to reduce the myocardial ischemia or infarction, but other workers did not found significant effects with the nitroglycerin. Rather recent clinical studies indicated that nitroglycerin, upon being intravenously injected, may increase the incidence of arrhythmias without modifying the infarction. Propranolol and the novel cardioselective beta-blocking compounds (Atenolol , Practolol, Metoprolol) have been used with the purpose of reducing the damage caused by the myocardial infarction. Some authors demonstrated in dogs with occlusion of the circumflex coronary arteria that Propranolol caused the necrosis to be significantly reduced. More recent studies, however, did not show significant effects for the Propranolol. Practolol demonstrated effects more interesting than Propranolol in the treatment of the myocardial ischemia, in a comparison study carried out in dogs by evaluating haemodynamic parameters, the oxygen consumption of the myocardium, lactate. The action of these drugs may be probably attributed to a reduction of the oxygen consumption of the myocardium, as a consequence of the blocking of the sympathic stimulation on the cardiac frequence and contractility. The calcium antagonizing drugs (Verapamil, Nifedipine, and others), cause the calcium channels to be blocked, and the tone of the vascular smooth muscles to be reduced whereby a coronary, but also systemic vasodilation is induced, moreover the blocking of the calcium flow causes the myocardial contractility and oxygen consumption to be reduced. Some authors found in dogs with occlusion of the circumflex coronary arteria a modest but significant reduction of the necrosis after pretreatment with Verapamil; at higher dosages the drug had hypotensive effects and induced a cardiac blocking of various grades. The results obtained with Nifedipine are rather controversial. The Nifedipine at high dosages causes in dogs a reduction of the aortic pressure, an increase of the cardiac frequency and an increase of the ischemic area; at low dosages it induces a lower pressure diminution and a slight reduction of the ischemic area. The anti-ischemia effects of Fendiline (negative chronotropic action, increase of the coronary flow) and of Felodipine (preventing action on the ventricle fibrillation induced by the occlusion of the descending coronary in pigs) have been recently described. The anti-arrhythmic action of Lidocaine, prevailingly attributed to direct electrophysiological effects, is especially interesting in the treatment on the ventricular arrhythmias associated with a sympathetic hyperactivity. Lidocaine, when intravenously injected, reduces the cardial sympathetic activity, this effect would be caused by a central action of the drug. Dipyridamole has a dilating action particularly on the coronary small arteriae; this drug is moreover able to interfere with the platelet functionality by potentiating the prostacyclin effect or by inhibiting the phosphodiesterases, whereby the intracellular cAMP is increased. Dipyridamole has induced, under some experimental conditions, an increase of the coronary haematic flow and a reduction of the ischemic area in dogs with occluded coronary artery. These effects of Dipyridamole are however not evident when the drug gives place to relevant pressure reduction. Sulfinpyrazone does inhibit the platelet aggregation and the biosynthesis of prostaglandins; this drug has relevantly reduced the ventricular arrhythmias and the incidence of the fibrillation in cats with occluded descending coronary. The extension of the ischemic area induced by the occlusion of the coronary however was not reduced by the treatment with Sulfinpyrazone. The use of prostacyclin (PGI₂) has been recently proposed for the treatment of the myocardial acute infarction. PGI₂ was found to be active in the reducing of the arrhythmias occurring in the early post-infarction phases in dogs and rats after ligation of the coronary artery Harvie C.J. et al; "The action of prostaglandin E₂ and F 1a on myocardial ischaemia - infarction arrhytmias in dogs". Prostaglandis 16 , 885-899, 1978; Cocker S.J. et al, "Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias". Nature, 291 , 323-324, 1981 and Au T.L.S. et al "The actions of proslaglandins I₂ and E₂ on arrhythmias procured by coronary occlusion in rats and dogs". Prostaglandins, 18 707-720, 1979). In a study of the protective effect of PGI₂ on the acute mycoardial ischemia induced in the cat, the hypothesis was made that PGI₂, administered by perfusion, does protected the ischemic myocardium by reducing the oxygen demand of the tissue, through a reduction of the cardiac work and, probably, by inhibiting the platelet aggregation and by preserving the integrity of the myocardial cells ( Ogletree M.L. et al, "Studies on the protective effect of prostacyclin in acute myocardial ischemia". Eur. J. Pharmacol., 56 95-103, 1979). From the above therapeutical picture, which has been necessarily reported in a very synthetic manner, it is clear that the problem of the treatment of the myocardial infarction and ischemia has not found to date a therapeutically satisfactory solution. It has now been found that the above identified therapeutical problem is essentially solved by means of a therapeutical composition which is characterized by containing, as the active ingredient, the substance called Defibrotide, i.e. a polydeoxyribonucleotide obtained by extraction from animal organs. Defibrotide (DCI, liste 21, Chronique OMS, 35 , 5 suppl. 4 (1981), is as above stated a polydeoxyribonucleotide (USP 3,829,567), obtained through extraction from animal organs (see U.S. Patents Nos. 3,770,720 and 3,899,481 to which reference is made for greater details), which is devoid of anticoagulating activity and of haemodynamic effects, showing relevant profibrinolytic and anti-thrombotic activity under different experimental conditions (Niada R. et al. "Antithrombotic activity of polydeoxyribonucleotides of mammalian origin (Laboratory Code: Fraction P) in experimental animals", VII International Congress on Thrombosis and Haemostasis (London 15-20 July 1979) Abs. No. 1162, Thrombosis and Haemostasis, 42 , 474, 1979 and Pescador R. et al. "Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit"- Thrombosis Research, 30, 1-11, 1983). It is particularly worth to mention that, as confirmed by the several studies published on Debifrotide, this active principle is practically devoid of toxicity as well as from objectionable side effects. It is also worth to mention that to date Defibrotide has found or is finding therapeutical use for pathologies which are essentially different from those contemplated by the present invention. In fact Defibrotide is indicated as antithrombotic drug, for the treatment of peripheral arteriopathies and for the care of states of acute renal insufficiency. These uses might not obviously suggest the results achieved by the present use, namely to provide a therapeutical means effective for the treatment of cases of myocardial acute ischemia and infarction which, as it can be appreciated from the previously mentioned situation, did not found to date an effective remedy. As it will be detailedly illustrated hereinafter, Defibrotide has been tested in a model of lethal acute myocardial ischemia in cats with total occlusion of the descending coronary arthery at its origin; the drug was injected in the vein (bolus injection followed by perfusion), after the occlusion upon the appearance of significant electrocardiographic alterations. Defibrotide, surprisingly, has been capable of reducing the electrocardiographic alteriations, of bringing to the normality the rate of creatine-phosphokinase in the myocardium and of protecting from the death all the treated animals. In the corresponding control group the death rate was 80%. More specifically it has been selected the model of ischemia induced by ligation of the left descending coronary artery in cats, according to the indications of Jennings ( Jennings R.B., "Early phase of myocardial ischemic injury and infarction. " Am. J. Cardiology, 24, 6 753-765, 1969; Jennings R.B. et al. "Lethal myocardial ischemic injury. " Am. J. Path., 102, 2, 241-255, 1981). According to this model the ligation, applied at the origin of the coronary artery, induces heavy electrocardiographic alterations (raising of the ST tract) as well as of haemodynamic and enzimatic nature, such as to cause the death of the animal (owing to ventricular fibrillation) in 12 of the 15 cats of the control group within the first 15 to 30 minutes after the occlusion. Defibrotide has been injected intravenously at the dose of 32 mg/kg as a "bolus" followed by perfusion of 32 mg/kg/hour, one minute after the coronary occlusion, when evident electrocardiographic alterations appear. All the animals treated with Defibrotide (10 cats) were protected from the death during the experiment (6 hours). The protecting effect of the drug has been also evaluated on the average aortic pressure and on the cardiac frequency; the values of these parameters, reduced in the early phases of the ischemia, have been significantly restored to the normal levels. The PRI index (average aortic pressure times cardiac frequency) which does indirectly indicate the oxygen consumption of the myocardial tissue, was increased by 50%, with respect to the control, in the animals treated with Defibrotide. The increase of creatine phosphokinase (CPK) in the plasma and its marked reduction in the ischemic tissue are modifications fully antagonized by the Defibrotide. According to this model also the effect of some known drugs, such as Trinitroglycerin (10 µg/ kg plus 300 µg/kg/hour i.v.), Lidocaine (2 µg/kg plus 6 µg/kg/hour i.v.), Atenolol (3 µg/kg plus 9 µg/kg/hour i.v.) Sulfinpyrazone (32 µg/kg plus 32 µg/kg/hour i.v.) Verapamil (1 µg/kg plus 3 µg/kg/hour i.v.) and Prostacyclin (30 or 60 nM/kg plus 30 or 60 nM/kg/hour iv. or by intracardiac perfusion)has been tested; all these drugs, under the above experimental conditions, did not protect the treated animals from the death. Only trinitroglycerin delayed the death time by about 2 hours, but no modification appeared as regards the haemodynamic and enzymatic parameters. Consequently the capacity of Defibrotide of protecting from the death all the cats affected by infraction under the same experimental conditions in which prostacyclin was ineffective is surprising. In Table I the more significant results obtained in the model of lethal ischemia are reported. These data indicate a therapeutical action of Defibrotide in the subject model of myocardial ischemia. Defibrotide injected intravenously (bolus injection followed by perfusion) after inducing the lethal ischemia, protected from death all the treated animals, restoring to normal levels the tested haemodynamic parameters and the values of creatine phosphokinase in the plasma and in the ischemic tissue. The tested known drugs did not protect from death and no modification was detected as regards the haemodynamic parameters. The subject matter of the present invention concerns the use of Defibrotide as the active ingredient for the preparation of pharmaceutical compositions for the treatment of myocardial acute ischemia, the compositions further comprising per se known standard vehicles and/or excipients- Likewise, the experimental evaluation was carried out of the action of Defibrotide in the case of non lethal myocardial infarction. According to the method of Jennings (Jennings R.B. et al. "Lethal myocardial ischemic injury. " Am. J. Path., 102, 2, 241-255,1981) and Oglotree ((Oglotree M.L. et al "Studies on the protective effect of prostacyclin in acute myocardial ischemia". European J. Pharmcol. 56, 95-103, 1979) the model of ischemia was selected which is induced by the ligation of the left descending coronary arteria in cats. In this model the ligation, applied at 12 to 14 mm from the origin of the coronary, caused the death of the animal only in few cases which were discharged from this study; the ischemia induced by this occlusion gives place to serious electrocardiographic alterations (raising of the ST tract) and to relevant haemodynamic and biochemical alterations. The following parameters were examined: electrocardiogram, aortic pressure cardiac frequency, PRI, creatine phosphokinase (CPK) in the plasma and CPK, lactate and ATP in the myocardial tissue. Defibrotide was perfused intravenously at the dose of 32 mg/kg/hour three hours before the ligation of the coronary and the perfusion was maintained for the whole period of the occlusion (5 hours). The drug was capable of significantly reduce the electracardiographic alteration (raising of the ST tract), of restoring the haemodynamic parameters and the CPK levels in the myocardial tissue and in the plasma to the normal values. The lactate increase and the ATP reduction, these modifications having been detected in the ischemic tissue, were fully antagonized by Defibrotide. In this experimental model only Atenolol was tested among the known drugs. Atenolol (1mg/kg/hour u.v.) has shown some protecting effect only on CPK; no modification has been noticed as regards the other tested parameters (both biochemical and haemodynamic). The pharmaceutical compositions can be formulated with techniques, excipients and vehicles of conventional and well known type, for the administration both orally and by injection, particularly by intravenous route. The foreseen dosages of active ingredient in the compositions shall vary between 50 and 1500 mg for unitary dose, whereas to attain the desired results the daily administration of 12 to 14 mg/kg is suggested.

Claims: Use of Defibrotide as the active ingredient for the preparation of pharmaceutical compositions for the treatment of myocardial acute ischemia, the compositions further comprising per se known standard vehicles and/or excipients. Use of Defibrotide according to claim 1, characterized in that said composition contains, for unitary dose, 50 to 1500 mg of Defibrotide. Use of Defibrotide according to claim 1, characterized in that said composition is in form suitable for oral administration . Use of Defibrotide according to claim 1, characterized in that said composition is in form suitable for intravenous administration.

Inventors: MANTOVANI, MARISA, NIADA, RICCARDO, PRINO, GIUSEPPE
Applicants: CRINOS INDUSTRIA FARMACOBIOLOGICA S.P.A.
Application year: 1985
Main classification: A61K31
IPC codes: A61K31, A61P9, C07H21